These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37871326)

  • 41. Treatment of refractory overactive bladder with OnabotulinumtoxinA vs PTNS: TROOP trial.
    Kopcsay KS; Marczak TD; Jeppson PC; Cameron AP; Khavari R; Tefera E; Gutman RE
    Int Urogynecol J; 2022 Apr; 33(4):851-860. PubMed ID: 34993598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis).
    Yokoyama O; Honda M; Yamanishi T; Sekiguchi Y; Fujii K; Nakayama T; Mogi T
    Int J Urol; 2020 Mar; 27(3):227-234. PubMed ID: 31957922
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Not Available].
    Bywater M; Kessler TM
    Praxis (Bern 1994); 2017; 106(21):1175-1181. PubMed ID: 29041854
    [No Abstract]   [Full Text] [Related]  

  • 44. Longitudinal urinary microbiome characteristics in women with urgency urinary incontinence undergoing sacral neuromodulation.
    Mueller MG; Das P; Andy U; Brennaman L; Dieter AA; Dwarica D; Kirby AC; Shepherd JP; Gregory WT; Amundsen CL
    Int Urogynecol J; 2023 Feb; 34(2):517-525. PubMed ID: 35608624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms.
    Abdel-Fattah M; Chapple C; Guerrero K; Dixon S; Cotterill N; Ward K; Hashim H; Monga A; Brown K; Drake MJ; Gammie A; Mostafa A; Bladder Health UK; Breeman S; Cooper D; MacLennan G; Norrie J
    Trials; 2021 Oct; 22(1):745. PubMed ID: 34702331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence.
    Chermansky CJ; Richter HE; Jacoby K; Titanji W; Jenkins B; Geib T; Brucker BM
    J Urol; 2022 Oct; 208(4):855-862. PubMed ID: 35830550
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Pro.
    Kraus SR
    J Urol; 2017 Sep; 198(3):501-502. PubMed ID: 28751015
    [No Abstract]   [Full Text] [Related]  

  • 48. Sacral Neuromodulation is Preferred over OnabotulinumtoxinA Injection for Overactive Bladder in Women: Con.
    Bales GT
    J Urol; 2017 Sep; 198(3):500-501. PubMed ID: 28751016
    [No Abstract]   [Full Text] [Related]  

  • 49. Different electrode positioning for transcutaneous electrical nerve stimulation in the treatment of urgency in women: a study protocol for a randomized controlled clinical trial.
    Padilha JF; Avila MA; Seidel EJ; Driusso P
    Trials; 2020 Feb; 21(1):166. PubMed ID: 32046754
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder.
    Baron M; Perrouin-Verbe MA; Lacombe S; Paret F; Le Normand L; Cornu JN
    Neurourol Urodyn; 2020 Mar; 39(3):1012-1019. PubMed ID: 32108383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does symptom severity predict response to low-dose onabotulinumtoxinA for the treatment of urgency urinary incontinence?
    Gonzalez HM; Wheat JE; Dengler KL; Barbier HM; Gehrich AP; Gruber DD; Warner WB
    Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():118-124. PubMed ID: 33212321
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Editorial Comment: Sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: impact on fecal incontinence symptoms and sexual function.
    Riccetto CLZ
    Int Braz J Urol; 2020; 46(4):671-672. PubMed ID: 32374138
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
    Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
    Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sacral nerve stimulation for urinary urge incontinence, urgency-frequency, urinary retention, and fecal incontinence: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(3):1-64. PubMed ID: 23074472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Outcomes of Sacral Neuromodulation in Patients with Prior Surgical Treatment of Stress Urinary Incontinence and Pelvic Organ Prolapse.
    Bartley JM; Ramirez V; Killinger KA; Boura JA; Gupta P; Gaines N; Gilleran JP; Peters KM
    Female Pelvic Med Reconstr Surg; 2017; 23(1):8-12. PubMed ID: 27636222
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized, double-blind, placebo controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia.
    Chughtai B; Dunphy C; Lee R; Lee D; Sheth S; Marks L; Kaplan SA; Te AE
    Can J Urol; 2014 Apr; 21(2):7217-21. PubMed ID: 24775575
    [TBL] [Abstract][Full Text] [Related]  

  • 57. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
    Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
    Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
    Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
    Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Concurrent Retropubic Midurethral Sling and OnabotulinumtoxinA for Mixed Urinary Incontinence: A Randomized Controlled Trial.
    Komar A; Bretschneider CE; Mueller MG; Lewicky-Gaupp C; Collins S; Geynisman-Tan J; Tavathia M; Kenton K
    Obstet Gynecol; 2021 Jan; 137(1):12-20. PubMed ID: 33278293
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
    Tilborghs S; De Wachter S
    Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.